Itacitinib adipate by Incyte for Cytokine Release Syndrome (Cytokine Storm): Likelihood of Approval
Itacitinib adipate is under clinical development by Incyte and currently in Phase II for Cytokine Release Syndrome (Cytokine Storm). According to GlobalData, Phase II drugs for Cytokine Release Syndrome (Cytokine Storm) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Itacitinib adipate LoA Report. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.Itacitinib adipate overviewItacitinib adipate (INCB-39110) is under development for the treatment of cytokine release syndrome, advanced solid tumor malignancies including sporadic hemophagocytosis lymphohistiocytosis (HLHs), advanced hepatocellular carcinoma, T-Cell Leukemia, soft tissue sarcoma such as leiomyosarcoma, synovial sarcoma, pleomorphic undifferentiated sarcoma, myxoid or round cell liposarcoma, transitional cell carcinoma, primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (PPV-MF), post essential thrombocythemia myelofibrosis (PET-MF), B-cell lymphomas including indolent, aggressive B-cell non- Hodgkin's lymphoma, chronic lymphocytic leukemia, hairy cell leukemia, Waldenstrom macroglobulinemia, mantle cell lymphoma, diffuse large B-cell lymphoma, Hodgkin's lymphoma, myelodysplastic syndrome, myeloproliferative neoplasms, relapsed and refractory overlap syndromes, metastatic non-small cell lung cancer, post-lung transplant bronchiolitis obliterans syndrome (BOS), acute myeloid leukemia(AML), acute lymphocytic leukemia (ALL). The drug candidate is administered orally as a tablet. INCB-39110 targets Janus kinase 1 (JAK1). The drug candidate was also under development for pancreatic ductal adenocarcinoma, moderate to severe ulcerative colitis, renal cell carcinoma, rheumatoid arthritis, chronic plaque psoriasis, endometrial cancer, gastric cancer, head and neck squamous cell carcinoma, melanoma, colorectal cancer, triple negative breast cancer, small cell lung cancer, urothelial cancer, ureter cancer, bladder, urethral cancer and acute graft versus host disease. Incyte overviewIncyte is a biopharmaceutical company, which discovers, develops and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis; and polycythemia vera who are intolerant to hydroxyurea. The company distributes Jakafi through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and cancer indications under the name Jakavi. The company’s pipeline portfolio encompasses drugs for the treatment of lung cancer, graft versus host disease, b-cell malignancies, solid tumors, non-small cell lung cancer, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US. For a complete picture of Itacitinib adipate's drug-specific PTSR and LoA scores, buy the report here.
Itacitinib adipate is under clinical development by Incyte and currently in Phase II for Cytokine Release Syndrome (Cytokine Storm).
What's Your Reaction?
